Vivos Therapeutics Inc (VVOS) - Net Assets
Based on the latest financial reports, Vivos Therapeutics Inc (VVOS) has net assets worth $-1.27 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($25.04 Million) and total liabilities ($26.31 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check VVOS tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-1.27 Million |
| % of Total Assets | -5.06% |
| Annual Growth Rate | N/A |
| 5-Year Change | -106.07% |
| 10-Year Change | N/A |
| Growth Volatility | 716.9 |
Vivos Therapeutics Inc - Net Assets Trend (2018–2025)
This chart illustrates how Vivos Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See Vivos Therapeutics Inc (VVOS) defensive interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Vivos Therapeutics Inc (2018–2025)
The table below shows the annual net assets of Vivos Therapeutics Inc from 2018 to 2025. For live valuation and market cap data, see Vivos Therapeutics Inc (VVOS) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-1.55 Million | -119.49% |
| 2024-12-31 | $7.95 Million | +1835.28% |
| 2023-12-31 | $411.00K | -91.44% |
| 2022-12-31 | $4.80 Million | -81.20% |
| 2021-12-31 | $25.54 Million | +50.96% |
| 2020-12-31 | $16.92 Million | +674.82% |
| 2019-12-31 | $-2.94 Million | -160.97% |
| 2018-12-31 | $4.83 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vivos Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11283346800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | % |
| Other Components | $123.87 Million | % |
| Total Equity | $-1.49 Million | 100.00% |
Vivos Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Vivos Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lupaka Gold Corp.
V:LPK
|
$7.11 Million |
|
Diamond Estates Wines & Spirits Inc
V:DWS
|
$7.11 Million |
|
International Graphite Ltd
AU:IG6
|
$7.12 Million |
|
Perrot Duval Holding SA
SW:PEDU
|
$7.13 Million |
|
Lions Bay Capital Inc
V:LBI
|
$7.10 Million |
|
Meihua International Medical Technologies Co. Ltd.
NASDAQ:MHUAF
|
$7.10 Million |
|
Advanced Blockchain AG
XETRA:BWQ
|
$7.10 Million |
|
Ajooni Biotech Limited
NSE:AJOONI
|
$7.10 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vivos Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 7,954,000 to -1,490,000, a change of -9,444,000 (-118.7%).
- Net loss of 21,230,000 reduced equity.
- New share issuances of 5,576,000 increased equity.
- Other factors increased equity by 6,210,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-21.23 Million | -1424.83% |
| Share Issuances | $5.58 Million | +374.23% |
| Other Changes | $6.21 Million | +416.78% |
| Total Change | $- | -118.73% |
Book Value vs Market Value Analysis
This analysis compares Vivos Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $10.45 | $0.51 | x |
| 2019-12-31 | $-5.93 | $0.51 | x |
| 2020-12-31 | $23.23 | $0.51 | x |
| 2021-12-31 | $30.07 | $0.51 | x |
| 2022-12-31 | $5.22 | $0.51 | x |
| 2023-12-31 | $0.34 | $0.51 | x |
| 2024-12-31 | $1.58 | $0.51 | x |
| 2025-12-31 | $-0.15 | $0.51 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vivos Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -121.71%
- • Asset Turnover: 0.69x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-533.39%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -174.84% | -222.54% | 0.46x | 1.70x | $-8.92 Million |
| 2019 | 0.00% | -94.39% | 1.51x | 0.00x | $-10.46 Million |
| 2020 | -71.27% | -92.28% | 0.52x | 1.50x | $-13.75 Million |
| 2021 | -79.44% | -120.15% | 0.50x | 1.32x | $-22.84 Million |
| 2022 | -496.67% | -148.81% | 1.17x | 2.86x | $-24.33 Million |
| 2023 | -3304.87% | -98.42% | 1.29x | 26.11x | $-13.62 Million |
| 2024 | -140.01% | -74.09% | 0.98x | 1.92x | $-11.93 Million |
| 2025 | 0.00% | -121.71% | 0.69x | 0.00x | $-21.08 Million |
Industry Comparison
This section compares Vivos Therapeutics Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,818,520,110
- Average return on equity (ROE) among peers: -48.87%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vivos Therapeutics Inc (VVOS) | $-1.27 Million | -174.84% | N/A | $7.10 Million |
| Abbott Laboratories (ABT) | $17.78 Billion | 20.28% | 1.23x | $153.89 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $19.91 Million | -270.00% | 1.43x | $15.55 Million |
| Aethlon Medical Inc (AEMD) | $-5.98 Million | 0.00% | 0.00x | $2.51 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $903.35K |
| Adapthealth Corp (AHCO) | $280.85 Million | -57.55% | 5.46x | $1.29 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $6.89 Million | 30.07% | 0.49x | $6.67 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $7.70 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $8.10 Million | -140.88% | 0.21x | $4.44 Million |
| Artivion Inc (AORT) | $17.90 Million | 7.26% | 0.20x | $1.03 Billion |
| Apyx Medical Inc (APYX) | $22.89 Million | 2.69% | 0.23x | $176.29 Million |
About Vivos Therapeutics Inc
Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnorma… Read more